{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-064180","form_type":"8-K","ticker":null,"cik":"0000727207","company_name":"Accelerate Diagnostics, Inc","filed_at":"2023-05-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.086879+00:00","generated_at":"2026-06-14T16:23:46.208844+00:00","sec_items":["3.03","5.07","5.02","5.03","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Accelerate Diagnostics shareholders approve 250M share increase, reverse split, and equity plan expansion","bullets":["Authorized common stock increased from 200M to 450M shares.","Reverse stock split approved at ratio between 1:5 and 1:30, exact ratio at Board discretion.","Equity plan share reserve increased by 16M for the 2022 Omnibus Incentive Plan.","Mark Black elected to Board per Restructuring Support Agreement.","Nine directors elected; Ernst & Young ratified as auditor for FY2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-064180","json":"https://secwatch.observer/filing/0001104659-23-064180.json","markdown":"https://secwatch.observer/filing/0001104659-23-064180.md","text":"https://secwatch.observer/filing/0001104659-23-064180.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/tm2316472d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T16:23:46.208844+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8144ca8f65720cfeb227744492180bb94a2144b3","claim":"Accelerate Diagnostics, Inc: Increased total authorized shares of capital stock from 205,000,000 to 455,000,000, with common stock increased from 200,000,000 to 450,000,000 and preferred stock unchanged at 5,000,000 (effective 2023-05-23).","evidence_excerpt":"On May 23, 2023, Accelerate Diagnostics, Inc. (the “Company”) filed a Certificate of Amendment to the Certificate of Incorporation of the Company (the “Certificate of Amendment”) with the Secretary of State of the State of Delaware to increase the total number of authorized shares of the Company’s capital stock to 455,000,000 shares, of which 450,000,000 shares are designated as common stock and 5,000,000 shares are designated as preferred stock.","evidence_source":"SEC 8-K Item 5.03/5.05/5.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","confidence":0.9,"family_label":"Governance Changes","details":[{"label":"Change","value":"charter amendment"},{"label":"Effective","value":"2023-05-23"}],"fact_type":"governance_change"},{"claim_id":"045e0e45ebd3a4cee05c575c8543aa052afcb4b9","claim":"Accelerate Diagnostics, Inc shareholders approved Ratification of Ernst & Young LLP as independent registered public accounting firm at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 6 – Ratification of Independent Registered Public Accounting Firm Votes For Votes Against Abstentions Broker Non-Votes 69,820,039 426,721 187,996 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"14ab1b85842c34212cad499f0bcd53b8e7caa03b","claim":"Accelerate Diagnostics, Inc shareholders approved Approval of Certificate Amendment to effect a reverse stock split at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 4 – Approval of Certificate Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split Votes For Votes Against Abstentions Broker Non-Votes 66,920,245 3,390,632 123,879 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"reverse split"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"864bccab07f0428fee8dbc80568ed86804ea5b7b","claim":"Accelerate Diagnostics, Inc shareholders approved Approval of Plan Amendment to increase authorized shares under the 2022 Incentive Plan at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 3 – Approval of Plan Amendment Votes For Votes Against Abstentions Broker Non-Votes 65,510,097 4,674,623 250,036 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"equity plan"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"d9f8c05397c772064f2ba2f075bed78b570659a5","claim":"Accelerate Diagnostics, Inc shareholders approved Election of 9 directors at the 2023-05-19 meeting.","evidence_excerpt":"On May 19, 2023, the Company held its 2023 Annual Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the Company’s shareholders: (1) elected 9 directors","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"e5fdd5cc8959580c6724f7c0ac65d590c30f0329","claim":"Accelerate Diagnostics, Inc shareholders approved Approval of Nasdaq Rule 5635(d) Proposal regarding issuance of common stock below minimum price at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 5 – Approval of Nasdaq Rule 5635(d) Proposal Votes For Votes Against Abstentions Broker Non-Votes 67,080,356 3,202,778 151,622 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"},{"claim_id":"fb4817e33eebfc2c0de6b90fa5c55781d626c31c","claim":"Accelerate Diagnostics, Inc shareholders approved Approval of Certificate Amendment to Increase Authorized Shares at the 2023-05-19 meeting.","evidence_excerpt":"Proposal No. 2 – Approval of Certificate Amendment to the Certificate of Incorporation to Increase Authorized Shares Votes For Votes Against Abstentions Broker Non-Votes 65,723,737 4,583,940 127,079 0","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/727207/000110465923064180/0001104659-23-064180-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"charter amendment"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-05-19"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}